Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Jun 1, 2026.

Back to dashboard

CommercialCoverageMedium impact

08.02.38a, Zenocutuzumab-zbco (Bizengri®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Jun 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new medical necessity criteria policy has been established for Zenocutuzumab-zbco (Bizengri®), a pharmacy drug. This policy will define coverage requirements and approval criteria for this medication starting June 1, 2026.

Action Required

Action needed

Before June 1, 2026: Review the full policy document at the provided URL to understand specific medical necessity criteria for Zenocutuzumab-zbco (Bizengri®). Update prior authorization protocols and ensure providers are aware of documentation requirements for this specialty oncology drug.

Related policy hubs

Independence Blue Cross policies Oncology Hematology